Allergy Institute Joins Secret Meeting Club This Week
Published Date: 1/7/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on February 5-6, 2025, to review and decide on grant applications related to microbiology and infectious diseases. This meeting affects researchers seeking funding and keeps sensitive information private. No public attendance is allowed, and the decisions could impact future research funding.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIH Grant Applications Reviewed Feb 5-6
On February 5-6, 2025, the National Institute of Allergy and Infectious Diseases (NIAID) will meet from 10:00 a.m. to 6:00 p.m. to review and evaluate grant applications for the Microbiology and Infectious Diseases Research Study Section. The meeting’s decisions could affect future research funding for applicants.
Meeting Closed; Confidentiality Protected
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) and conducted as a video assisted meeting in Rockville, MD. Discussions may disclose confidential trade secrets, patentable material, or personal information, and those materials will be kept private to avoid unwarranted invasion of privacy.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20710, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Modify the Required Criteria To Qualify for the Reduced Incremental Fee
Investors Exchange (IEX) is changing the rules for who can get a discount on certain trading fees. Starting November 1, 2026, members will need to meet new criteria to qualify for the reduced incremental fee, which could save or cost them money depending on their trading activity. This change affects all IEX members and kicks in right away to keep things fair and clear.
2026-20729, Proposed Agency Information Collection Activities; Comment Request
The National Credit Union Administration (NCUA) wants to update its Call Report form to include questions about credit unions’ activities with payment stablecoins. This change affects all credit unions and will start with reports due March 31, 2027. The NCUA is asking for public comments by December 8, 2026, to make sure the new form works well without causing extra costs or hassle.
2026-20702, Notice of Public Meetings of the Virginia Advisory Committee to the U.S. Commission on Civil Rights
The Virginia Advisory Committee to the U.S. Commission on Civil Rights is holding virtual public meetings to discuss how Virginia public universities are following rules about fair student admissions. Anyone interested can join these Zoom meetings on October 27, November 10, and December 15, 2026, to listen and share their thoughts. These meetings don’t cost money to attend, but phone users might pay regular call fees.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
2026-20779, Passenger Vehicle and Light Truck Tires From Thailand: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that tires from Thailand were sold in the U.S. for less than their normal price between July 2024 and June 2025. This means some importers might have to pay extra duties to keep things fair. The review process had some delays due to government shutdowns, but now the preliminary results are out and open for comments.
Previous / Next Documents
Previous: 2025-00109, National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting
The National Institute on Deafness and Other Communication Disorders is holding a closed virtual meeting on February 14, 2025, to review grant applications for voice, speech, and language research. This meeting is private to protect sensitive information and personal privacy. Researchers applying for these grants should note the review date as it impacts funding decisions.
Next: 2025-00111, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on February 19-20, 2025, to review and decide on grant applications. This meeting affects researchers seeking funding for allergy, immunology, and infectious disease projects. The discussions are private to protect sensitive information and personal privacy, ensuring fair and secure funding decisions.